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Background: Fitness costs and slower disease progression are associated with a cytolytic T lymphocyte (CTL)
escape mutation T242N in Gag in HIV-1-infected individuals carrying HLA-B*57/5801 alleles. However, the impact
of different context in diverse HIV-1 strains on the fitness costs due to the T242N mutation has not been well
characterized. To better understand the extent of fitness costs of the T242N mutation and the repair of fitness loss
through compensatory amino acids, we investigated its fitness impact in different transmitted/founder (T/F) viruses.
Results: The T242N mutation resulted in various levels of fitness loss in four different T/F viruses. However, the fitness
costs were significantly compromised by preexisting compensatory amino acids in (Isoleucine at position 247) or
outside (glutamine at position 219) the CTL epitope. Moreover, the transmitted T242N escape mutant in subject CH131
was as fit as the revertant N242T mutant and the elimination of the compensatory amino acid I247 in the T/F
viral genome resulted in significant fitness cost, suggesting the fitness loss caused by the T242N mutation had
been fully repaired in the donor at transmission. Analysis of the global circulating HIV-1 sequences in the Los
Alamos HIV Sequence Database showed a high prevalence of compensatory amino acids for the T242N mutation
and other T cell escape mutations.
Conclusions: Our results show that the preexisting compensatory amino acids in the majority of circulating HIV-1
strains could significantly compromise the fitness loss due to CTL escape mutations and thus increase challenges
for T cell based vaccines.
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Transmitted/founder virus, ReversionBackground
Soon after HIV-1 infection, hosts mount potent CTL re-
sponses [1-3]. However, HIV-1 can quickly develop resist-
ance by generating escape mutations to mitigate the
potency of the CTL responses [2-4]. These CTL escape
mutants may have reduced viral fitness and lowered viral
loads which can lead to slower disease progression or re-
duced probabilities of transmission to new hosts [5-10]. A
recent study showed dominant viral quasispecies with
higher in vivo fitness levels had an overall transmission
advantage and even marginally reduced viral fitness might* Correspondence: fgao@duke.edu
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unless otherwise stated.lower the overall transmission rates and offer long-term
benefits upon successful transmission [11]. However, the
better clinical outcome may not be sustained into chronic
infection [10], possibly due to subsequent compensatory
mutations that occur both within and outside the targeted
epitopes and repair the fitness loss [10,12-16].
The T242N mutation in the HLA-B*57/5801-restricted
TW10 epitope in Gag p24240–249 (TSTLQEQIGW) has
been widely studied for its impact on viral fitness, patho-
genesis, and disease progress [8,10,14,15] as well as the
repair of its fitness costs by compensatory mutations in
heterologous viral backbones [7,14,15,17]. However, the
fitness costs of the T242N and other T cell escape muta-
tions have been exclusively studied in unrelated heterol-
ogous viral backbones, in which the presence of unknownThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pretation of results. Moreover, since fitness costs of the
T242N mutation have not been studied in transmitted/
founder (T/F) viral genomes, it remains unknown how the
context of different T/F genomes affect its fitness impact,
especially in the cognate T/F viruses from which the
T242N mutation was selected or in the transmitted
T242N mutants. Studies have shown that T cell escape
mutations with little or no fitness costs can be prevalent
in the HLA matched and mismatched populations [18] or
persist for a long time without reverting back to the wild
type [19,20]. Thus, the increased prevalence of the CTL
escape mutations consequent on preexisting compensa-
tory amino acids at the population level may further re-
duce benefits of the protective HLA alleles to slow HIV
disease progression, posing challenges for T cell based
vaccines.
Using an unmodified infectious T/F molecular clone
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Figure 1 Replication kinetics of T cell escape mutants. Frequencies of
by comparing the longitudinal sequences to the T/F sequences for CH58 (
T242N escape mutation and compensatory amino acids were introduced into
kinetics of the mutants and their corresponding T/F viruses were determined
amino acids associated with T cell escape at the position 242 are indicated in
loss at the positions 219 and 247 are indicated in blue. Each virus was culturepreviously reported that the T242N mutation had a sig-
nificant fitness cost in its cognate T/F virus but the fit-
ness loss could be fully repaired by the compensatory
mutations in the same TW10 epitope [21,22]. To fully
understand the impact of the T242N mutation on viral
fitness, we now investigated its fitness costs and the
compensation in four additional T/F viruses.
Results and discussion
The CTL escape mutation T242N caused various levels of
fitness loss in different virus backbones
The T242N mutation was first detected 45 days post
screening and was fixed in the viral population at day
350 in patient CH58 who was positive for HLA-B*57,
which presents TW10 (Figure 1a), while it was not se-
lected in CH470 and CH40 (Figure 1b and c), neither of
which carry HLA-B*57/5801 alleles [3,4]. A G248E mu-
tation was also detected at the same time when the
T242N mutation occurred in CH58. However, it becamec
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mutations in the TW10 epitope or CypA binding loop were determined
a), CH470 (b), and CH40 (c). The days post screening are indicated. The
the CH58 (d), CH470 (e), and CH40 (f) T/F viral genomes. The replication
by measuring p24 concentrations in the cell culture supernatants. The
red while the amino acids associated with compensation of the fitness
d in triplicate. Mean values ± standard deviations are shown.
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viral population at day 350. Our previous study showed
that the T242N mutation resulted in a significantly re-
duced T cell response while the G248E mutation only
modestly affected T cell responses. The G248E mutation,
however, abrogated binding of KIR3DL1 to HLA-B*5703,
suggesting the emergence of this mutation was more likely
associated with NK cell recognition [23]. Since the G248E
was not clearly associated with T cell escape, it existed
only transiently in the viral population, and the focus of
the currently study was to determine fitness costs of the
T242N mutation in different genetic backgrounds, the
G248E mutation was not further studied.
To determine whether the T242N mutation could
cause similar fitness loss in different viral backbones, we
introduced it into these three T/F genomes. All three
T242N mutants replicated as well as their corresponding
T/F viruses when the T/F and T242N mutant viruses
were cultured independently (Figure 1d-f ). We then de-
termined their relative fitness by growing both the
T242N mutant and its corresponding T/F virus in the
same culture and determining the proportion of each
virus over time using the parallel allele-specific sequen-
cing (PASS) method, in which two compared viruses
(wild type and mutant) were grown in the same cell cul-
ture, and proportions of the viruses at different time
points were determined by directly detecting the wild
type and mutant bases in the viral genomes through
analysis of a large number of viruses in the culture
supernatant [21,22]. In all three comparisons, the T242N
mutants were outgrown by the corresponding T/F vi-
ruses over time in the culture (Figure 2a-c). Using the
mathematical model that we developed earlier [21,22],
we found that all three T242N mutants were significantly
less fit than their corresponding T/F viruses (p = 0.04 for
CH58T242N and CH40T242N; p = 0.007 for CH470T242N).
However, the fitness losses caused by the T242N mutation
were different among these three T242N mutants. It
was 11 ± 4% less fit for CH40T242N and 8 ± 3% less fit
for CH58T242N, but only 2 ± 1% less fit for CH470T242N
(Figure 2a-c). These results demonstrated that the T cell
escape mutation T242N could decrease the viral fitness
in different T/F viruses but the levels of fitness loss var-
ied in the different virus backbones.
The difference of the Malthusian growth parameters
characterizing two viral strains is not the only factor that
controls competition. For example, a virus that can in-
fect a cell fast and prevent superinfection will show an
advantage in a competitive assay, even if its overall
growth rate is not high. In addition, the estimates of
Malthusian parameters often have rather large errors, of
order 5% or more, due to variations in the growth rate
seen among replicate experiments. Since this level of
variation is similar to the competitive advantage that hasbeen observed in many cases, to reveal a fitness advan-
tage of this magnitude, we would need to grow the virus
in replicate experiments under almost identical condi-
tions. In practice, since one cannot control the condi-
tions that accurately between replicates, one needs to
simultaneously grow the viruses one wishes to compare.
The fitness loss due to the T242N mutation could be
compromised by the preexisting compensatory amino acids
Examination of the TW10 epitope sequences in these
three viruses showed that they all had Isoleucine (Ile) at
position 247 (Figure 1a-c), which could compensate the
fitness loss caused by the T242N mutation in CH77 but
neither I247 nor V247 alone had detectable fitness im-
pact on the cognate T/F virus [22]. The V247I mutation
was selected by T cell responses before the T242N T cell
escape mutation in CH77 which had Val at position 247.
It subsequently served as a compensatory mutation to
significantly restore the fitness loss caused by the T242N
mutation that was selected by later T cell responses [22].
To determine if the preexisting I247 also mitigated the
T242N mutation’s impact in these T/F viruses, we re-
moved this potential compensatory amino acid by intro-
ducing the I247V mutation into each T242N mutant to
generate double mutant viruses (NV). Both CH58NV and
CH470NV replicated similarly to their T/F viruses and
T242N mutants (Figure 1d and e). However, CH40NV
completely lost its replicative capacity as reported for
some other lethal mutations in the replication compe-
tent HIV-1 genome [24,25]. Examination of the cyclo-
philin A (CypA) binding loop sequences showed that the
glutamine at position 219, which can compensate fitness
costs due to the T242N mutation [7,14,26,27], was
present only in the CH40 T/F virus. Therefore, we intro-
duced the Q219H mutation into CH40T242N to generate
double mutant CH40HN, which also replicated as well as
its T/F virus and T242N mutant (Figure 1f ). When com-
pared to the corresponding T/F viruses, more fitness loss
were observed for all three double mutant viruses;
CH58NV, CH470NV and CH40HN were 14 ± 4%, 5 ± 3%
and 25 ± 3% less fit than the corresponding T/F viruses,
respectively (Figure 2d-f ). These results showed that the
T242N mutants without the compensatory amino acids
were significantly less fit than the corresponding T/F vi-
ruses and the T242N mutants with the compensatory
amino acids.
To determine if the compensatory amino acids alone
could cause fitness loss and contributed to the increased
fitness loss in the NV or NH double mutants, we generated
T/F mutants that contained the compensatory amino acids
but not the T242N mutation (the I247V mutation in CH58
and CH470 as well as the Q219H in CH40; Figure 1d-f).
All three mutants (CH58I247V, CH470I247V and CH40Q219H)


























Figure 2 Fitness loss caused by the T242N mutation was partially restored by the preexisting compensatory amino acids. The same
amount (2.5 ng p24) of the T/F and its mutant was mixed to infect freshly purified CD4+ T cells, and the proportion of each virus in the culture
was determined by the PASS fitness assay. The relative fitness of the T242N mutants was determined for CH58 (a), CH470 (b), and CH40 (c) by
comparing each T242N mutant to its corresponding T/F virus. The increased fitness loss of the T242N mutants after removing the compensatory
amino acids was determined for CH58 (d), CH470 (e), and CH40 (f) by comparing each double-mutation virus to its corresponding T/F virus. The
impact on fitness in the T/F viruses by the compensatory amino acids alone was determined by introducing those amino acids in the corresponding
T/F viral genomes for all three viruses: CH58I247V (g), CH470I247V (h) and CH40Q219H (i).
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their corresponding T/F viruses, CH58I247V, CH470I247V
and CH40Q219H did not change their proportions with
the T/F viruses throughout the culture (Figure 2g-i).
These results indicated that the compensatory amino
acids alone had no impact on the viral fitness and that
the increased fitness loss in double mutants (CH58NV,
CH470NV and CH40HN) was indeed due to the removal
of compensatory amino acids. Taken together, our data
demonstrated that the fitness costs caused by the T242N
mutation could be significantly mitigated by preexisting
compensatory amino acids.
The transmitted CTL escape T242N mutant had no
significant fitness costs
The transmitted CTL escape mutants carrying the
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Figure 3 Fitness impact of the T242N mutation and its compensatory
frequency of the T242N escape mutation in the TW10 epitope was determ
sequence. The days post screening are indicated. (b) The N242T reversion
genome and the replication kinetics of the mutants and their correspondin
cell culture supernatants. (c) The relative fitness of the T242N reversion mu
the PASS fitness assay. (d) The fitness cost of the T242N mutant was determ
mutation but not the compensatory isoleucine at position 247 to the T/F vwild type viruses [7,8,10]. However, the T242N escape
mutant viruses were frequently transmitted into new
hosts and its reversion back to the wild type generally
took months or years [7,10,27,28]. These observations
suggested that the T242N mutants might not be less fit
than the wild type viruses. However, the fitness impact
of the T242N mutation has not been determined in the
cognate transmitted T242N escape mutant. CH131 was
infected with a T242N escape mutant and did not have
the HLA-B*57/5801 alleles [4]. The reversion of the
T242N mutation was first detected at day 273 and was
fixed at day 670 (Figure 3a). To determine whether the
T242N reversion mutation (N242T) could render the
transmitted T242N escape mutant more fit, we gener-
ated the N242T reversion mutant by substituting N242
with T242 in the CH131 T/F viral genome and compared
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when cultured independently (Figure 3b). When co-
cultured with the CH131 T/F virus, no significant fitness
difference was observed between CH131 T/F and
CH131N242T viruses (Figure 3c). To test whether the ab-
sence of detectable fitness costs of the T242N mutation
in the T/F virus was due to the presence of compensa-
tory I247, we generated the CH131I247V mutant by
introducing the I247V mutation in the T/F viral gen-
ome (Figure 3b). Indeed, CH131 without the compen-
satory amino acid I247 (CH131I247V) was 12 ± 1% less
fit than the T/F virus (p = 0.002) (Figure 3d).
These results demonstrated that the impaired fitness
of the transmitted T242N escape mutant was fully
repaired by the compensatory amino acid I247. Thus,
the T/F virus, although carrying a fitness-impairing T
cell escape mutation, could be as infectious and trans-
missible as the wild type virus. Since the reversion of the
T242N to the wild type did not have any impact on the
fitness of the escape mutant, the reversion of the T242N
escape mutation would take a long time to occur in
CH131 and as reported in other studies [7,10,27,28].
These results also suggested that the reversion of preex-
isting T cell escape mutations whose fitness loss was well
compensated by the compensatory amino acids might
not affect viral fitness.
The fixation of fitness-impairing T242N mutation did not
lead to the viral load decrease
A small fitness difference may cause significant change
in viral populations [29]. Thus, the significant fitness
cost of the T242N mutation could have caused a signifi-
cant viral load (VL) decrease if it was fixed in the viral
population. However, no VL decrease was observed in
CH77 and CH58 after the T242N escape mutation was
fixed in the viral population (Figure 4). Such an absence
of VL decrease in CH77 might be due to the completeFigure 4 Association of the T242N mutation with the viral load. The v
five HIV-1 infected subjects. The T cell escape mutation T242N was selected
T242N escape mutant. The time for the first detection of the T242N escape
indicated by open triangle and the time for the fixation of the T242N or N
T242N mutation was detected in CH40 and CH470.repair of the fitness loss by the compensatory mutations
[21,22]. However, VL did not decreased in CH58 either,
although the T242N escape mutant was significantly less
fit than the T/F virus (Figure 4). Similar lack of VL de-
crease was also observed in other studies [4,30]. This
pervasive lack of association between the fixation of the
T242N mutation and the VL decrease suggested that the
significant fitness costs were generally compensated dur-
ing fixation. The slow fixation of the reversion mutation
T242N in the viral population in CH131 (397 days be-
tween the first detection and the fixation) (Figure 4) and
other viruses [7,10,27,28] lends further support to the
view that the fitness cost of the T242N mutation was
well compensated.
The high prevalence of compensatory amino acids in the
global circulating HIV-1 viruses could readily compromise
the fitness loss caused by the T cell escape mutations
I247 is present in the vast majority (94%) of the circulat-
ing virus sequences in the Los Alamos HIV sequence
database. Thus, the clinical benefits of the T242N escape
mutation could be mitigated significantly since the pre-
dominance of the compensatory amino acid can readily
counteract the fitness loss of the T242N escape mutants
in those individuals, as shown in a recent study in which
the high population-level frequency of compensatory
mutations for T cell escape mutation in TW10 and KF9
epitopes were found associated with limited protective
effect of the B*5801 allele [31]. The T242N mutation is
present in 13% of viruses in the Los Alamos HIV se-
quence database (Figure 5), suggesting that the T242N
CTL escape mutant is frequently transmitted and does
not revert back quickly. Interestingly, the T242N muta-
tion is almost exclusively (95%) found linked to Q219
and/or I247 in the database (Figure 5). Similar results
were obtained for the escape mutations in three other
CTL epitopes (TL9, KF11 and ISW9) for which theiral load set points were stabilized from ~100 days after screening in
in vivo in subjects CH77 and CH58. CH131 was infected with the
mutation (blue and brown) or the N242T reversion mutation (red) is
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Figure 5 The prevalence of the T cell escape mutations in T cell epitopes with or without compensatory amino acids. One sequence
from each HIV-1 infected individual in the Los Alamos HIV-1 Sequence Database was analyzed for four well-studied T cell epitopes (TW10, TL9,
KR11 and ISW9). Over 4000 sequences were analyzed for each epitope. The frequency of the sequences with the CTL escape mutations and the
frequency of the CTL mutant sequences with and without the compensatory amino acids were determined for each CTL epitope.
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(Figure 5).
The presence of T cell escape mutations and their
compensatory amino acids in a large proportion of HIV-
1-infected population, especially in the individuals with-
out restricting HLA alleles, suggested that viruses that
escaped from the T cell responses but had its fitness loss
restored by compensatory amino acids could successfully
transmit to new hosts with or without restricting alleles.
Since the transmitted viruses with both T cell escape
mutations and their compensatory amino acids could be
as fit as the wild type viruses, It will be unlikely for them
to quickly revert back to the wild type sequences and re-
sult in the high prevalence of the CTL escape mutations
and compensatory amino acids in large proportions of
the general viral population. If escape mutations accu-
mulate at a high frequency and become predominant (or
consensus), it may not be possible to observe their effect
[36]. Thus, this effect can be best seen when HLA alleles
are examined with lower frequencies. However, the fact
that we observed this in four alleles is consistent with
this not being a rare phenomenon.
Conclusions
We demonstrated that the fitness loss caused by the
T242N mutation could be significantly affected by the
differing context of viral backbones because of preexist-
ing compensatory amino acids that either were present
in the general viral population (CH40, CH470 and
CH58) or selected by immune responses (CH77) [21,22].
Thus, high prevalence of the compensatory amino acidscould significantly mitigate the benefits of the fitness
costs caused by the T242N escape mutation (Figure 6).
These results indicate that true fitness costs of T cell es-
cape mutations will be better revealed by analyzing those
escape mutations in the context of their cognate T/F
viral genomes or in multiple viral backbones when the
infectious cognate T/F clones are not available. Our data
also shows that the potential clinical benefits of T cell
escape mutations should not be analyzed independent of
compensatory mutations. More importantly, the fitness
compensation effects on the T cell escape mutations by
those preexisting compensatory amino acids should be
considered for the design of T cell based vaccines. If the
fitness loss caused by a T cell escape mutation can be
readily restored by the preexisting compensatory amino
acids or mutations, the vaccine-elicited T cell responses
may not control such viruses as effectively as T cell es-
cape mutant viruses that contain no compensatory
amino acids or mutations to restore fitness loss.
Importantly, the transmitted T242N escape mutant
could be as fit as the wild type virus, suggesting its fit-
ness loss could have been fully repaired by the compen-
satory amino acids in the donor at the transmission as
observed in CH77 [21,22]. With little or no fitness costs,
some CTL escape mutants could be as transmissible and
pathogenic as the wild type viruses. More importantly,
since those T cell escape mutant viruses have little or no
fitness costs, they will not revert back to wild type and
can persist for a long time in the newly infected popula-
tion [19,20]. As a result, the T cell escape mutations can
be present at high percentages in the HLA matched and
Virus with compensatory 
amino acids 
Virus without compensatory 
amino acids 
Selection 
pressure of T 
cell responses 
Escape Escape 
Significant fitness loss Mitigated fitness loss 
Likely slow disease progression Likely poor disease progression 
Figure 6 Interaction among host immune selection, escape, viral fitness and potential disease progression.
Liu et al. Retrovirology 2014, 11:101 Page 8 of 11
http://www.retrovirology.com/content/11/1/101mismatched populations (Figure 5) [18]. The high level
prevalence of the CTL escape mutations may reduce the
benefits of the protective HLA alleles to slow HIV dis-
ease progression and pose challenges for T cell based
vaccines. The implication for T cell vaccines is that T cell
responses, including in those who share HLA alleles and
induce T cell responses targeting the same epitopes, may
not affect fitness costs uniformly among vaccinees. Thus,
Immunogen designs that consider fitness costs of T cell
escape in the context of the entire HIV-1 protein [37-39]
may prove more efficacious.
Methods
Site-directed mutagenesis
Infectious molecular clones (IMCs) for CH40, CH58,
CH470, and CH131 T/F viruses were generated in previ-
ous studies [40,41]. Mutations at positions 219, 242, 247
in Gag were introduced into the T/F IMCs by using the
QuikChange II Site-Directed Mutagenesis Kits (Stratagene,
Santa Clara, CA). All final mutant clones were sequence
confirmed. The viral stocks were generated by transfecting
the IMCs into 293 T cells as previous described [42].
Viral replication kinetics
Peripheral blood mononuclear cells (PBMC) were ob-
tained through leukophereses from healthy donors under
clinical protocols approved by the Duke University Insti-
tutional Review Board. PBMCs were isolated using the
Ficoll-Hypaque density gradients and lymphocytes were
isolated by elutriation using standard techniques. CD4+
T cells were negatively selected from PBMCs or lympho-
cytes on an QuadroMACS Separator (Miltenyi Biotec,
Auburn, CA) using the CD4+ T cell Isolation Kit II
(Miltenyi Biotec, Auburn, CA). Fresh purified CD4+ T
cells were stimulated for three days in RPMI1640 contain-
ing 10% fetal bovine serum (FBS), interleukin 2 (IL-2)
(32 IU/ml; Advanced Biotechnologies, Columbia, MD),soluble anti-CD3 (0.2 μg/ml; eBioscience, San Diego, CA)
and anti-CD28 (0.2 μg/ml; BD Bioscience, San Diego,
CA). After stimulation, 50 μl of cell suspension (5 × 105
cells) was seeded into each well of a 96-well plate, and in-
fected with individual virus (500 TCID50) at 37°C for
4 hours. The cells were then washed three times with
RPMI 1640 and cultured in a 48-well plate with 300 μl of
RPMI1640 containing 10% FBS and IL-2 (32 IU/ml). The
culture supernatant (50 μl) was harvested daily and the
same volume fresh medium was replenished. The viral
replication was monitored by measuring the p24 concen-
tration in the culture supernatant using the Alliance HIV-
1 P24 ANTIGEN ELISA Kit (PerkinElmer, Waltham,
MA). All infections were performed in triplicate.
PASS fitness assay
CD4+ T cells (5 × 105) were infected with the mixture of
two compared viruses (2.5 ng of p24 for each virus). The
culture supernatant was harvested daily by completely
replacing the culture medium. The viral replication kin-
etics was monitored by determining the p24 concentra-
tion in the supernatant. The culture supernatants were
first treated with DNase (New England Biolabs Inc.,
MA, US) at 37°C for 20 minutes. Viral RNA (vRNA)
was extracted from 50–100 μl of the treated culture su-
pernatants and eluted into 20 μl of RNase free water
using the PureLink Viral RNA/DNA Mini Kit (Invitrogen,
Carlsbad, CA). vRNA (17 μl) was used for cDNA
synthesis using SuperScript III reverse transcriptase
(Invitrogen, Carlsbad, CA) with the primer lower3 (5’-
TTTTTCCTAGGGGCCCTGCAATTT-3’; nt 1998–2021
in HXB2). The percentage of each virus in the culture
supernatants was determined as previously described
[21,43]. Briefly, 20 μl of 6% acrylamide gel mix, containing
1 μM acrydite-modified reverse primer M6F2 (5’-
Acry-CTCGACGCAGGACTCGGCTTGCTG-3’; nt 685–
708), viral cDNA, 0.3% diallyltartramide, 5% Rhinohide,
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tetramethylethylenediamine (TEMED) and 0.2% bovine
serum albumin (BSA), was used to cast the gel on a bind-
saline (Amersham Biosciences, Piscataway, NJ) treated
glass slide. The in-gel PCR amplification was then per-
formed in a PTC-200 Thermal Cycler with a mix of
1 μM forward primer M6R2 (5’-TCCTCCCACTCCCT
GACATGCTGTCATCATTTC-3’; nt 1822–1854), 0.1%
Tween-20, 0.2% BSA, 1xPCR buffer, 100 μM dNTP mix,
3.3 units of Jumpstart Taq DNA polymerase (Sigma, St.
Louis, MO), and H2O (up to 300 μl) under a sealed
SecurSeal chamber (Grace Bio-Labs, Inc., Bend, OR).
The partial gag gene (1164 bp-1183 bp) was amplified.
The PCR conditions were 94°C for 3 min; 65 cycles of
94°C for 30 sec, 56°C for 45 sec, and 72°C for 3 min;
and 72°C for 6 min. After in-gel PCR, the gels were
treated with denaturation solution to remove the free
DNA strands. Single base extension (SBE) was then
performed to distinguish the compared viruses using
two different labeled bases with sequencing primers
that annealed just upstream of the target sites. To de-
tect the bases at position 242, sequencing primer
CH40/58_TW10 (5’-CATCCATCCTATTTGTTCCTGAA
GG-3’; nt 1515–1539) was used for CH40 and CH58,
and sequencing primer CH470_TW10: (5’-CATCCATGC
TATTTGTTCCTGAAGG-3’; nt 1515–1539) for CH470
and CH131. To detect the bases at the compensatory
amino acid sites, sequencing primer CH58_247 (5’-ATAG
GTGGATTACTTGTCATCCATCCTA-3’; nt 1529–1556)
and CH470_247 (5’-ATAGGTGGATTATTTGTCATCC
ATGCTA-3’; nt 1529–1556) were used for determining
position 247 in CH58 and CH470, respectively; CH40_219
(5’-TCATCTGGCCTGGTGCAACAGGCCCTGC-3’; nt
1447–1474) for determining position 219 in CH40;
CH131_247 (5’-GGTGGGTTACTTGTCATCCATGCTA-
3’; nt 1529–1553) for CH131. After SBE, the gel was
scanned to acquire images with the GenePix 4000B
Microarray Scanner (Molecular Devices, Sunnyvale, CA).
The two channel images (Cy5 and Cy3 for the bases
from the two compared virus templates, respectively)
were first cropped with Picture Window Pro3.5 (Digital
Light & Color, Belmont, MA) to remove the edge area
containing no specific signals. The cropped images were
then analyzed with the Progenesis PG200 software
(Nonlinear Dynamics, Durham, NC). After background
subtraction, normalization, and spot filter setting, only
unambiguous spots at both channels were included for
further analysis. The normalized pixel count data at two
mutation sites at each spot were exported into an Excel
file with a unique identifier. By comparing each spot’s
normalized values at both channels, the different viruses
were identified based on the base identity, and the per-
centage of each compared virus in the viral population
was then determined as previous described [21,22,43].Model for relative fitness
The relative fitness (Sij) is determined in competitive as-
says by measuring the relative replication slope of the vi-
ruses in culture over time using the mathematical model
described previously [21,22]. There are two sources of
statistical uncertainty in the measurement of slope: one
arising from the binomial fluctuations expected of the
counts in the PASS assay, and the other due to the dif-
ferences between the three replicates of each competi-
tion assay. In general, the inter-experiment differences
were much larger than the binomial estimation uncer-
tainty. We, therefore, quote this error, and use Student’s
t-test to assess the significance of the measured fitness
difference. All the statistical analyses were done using
the statistical package R [44] with the subplex [45] and
ucminf [46] libraries to do the parameter estimations
and using the gplots [47] library for visualization.
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